Hepatitis C and injecting drug use: impact, costs and policy options

DSpace Repository


URI: http://hdl.handle.net/10900/81818
Dokumentart: Book
Date: 2004
Source: EMCDDA Scientific Monograph Series ; (2004) 7
Language: English
Faculty: Kriminologisches Repository
Department: Kriminologie
DDC Classifikation: 360 - Social problems and services; associations
610 - Medicine and health
Keywords: Europäische Union , Drogenmissbrauch , Hepatitis C
Show full item record


Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph. A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication presents analyses on the impact and costs of the disease among injecting drug users, as a basis for sound policy-making. Other issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy. Hepatitis C affects an estimated 170 million people worldwide and at least a million, but possibly several million, people in Western Europe who are at risk of developing liver cirrhosis or liver cancer. It is a highly infectious and potentially fatal blood-borne disease that attacks the liver and for which there is as yet no vaccine.

This item appears in the following Collection(s)